000			01823 a2200469 4500
005			20250515000713.0
264		0	_c20060201
008			200602s 0 0 eng d
022			_a1462-3846
040			_aNLM _beng _cNLM
100	1		_aIoannidis, John
245	0	0	_aHIV: prevention of opportunistic infections. _h[electronic resource]
260			_bClinical evidence _cJun 2005
300			_a834-53 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_a2-Aminopurine _xanalogs & derivatives
650	0	4	_aAIDS-Related Opportunistic Infections _xprevention & control
650	0	4	_aAcyclovir _xtherapeutic use
650	0	4	_aAnti-Bacterial Agents _xtherapeutic use
650	0	4	_aAnti-HIV Agents _xtherapeutic use
650	0	4	_aAntifungal Agents _xtherapeutic use
650	0	4	_aAntitubercular Agents _xtherapeutic use
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aAzithromycin _xtherapeutic use
650	0	4	_aChickenpox _xprevention & control
650	0	4	_aClarithromycin _xtherapeutic use
650	0	4	_aCytomegalovirus Infections _xprevention & control
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFamciclovir
650	0	4	_aGanciclovir _xtherapeutic use
650	0	4	_aHerpes Simplex _xprevention & control
650	0	4	_aHumans
650	0	4	_aMycobacterium avium-intracellulare Infection _xprevention & control
650	0	4	_aMycoses _xprevention & control
650	0	4	_aPneumonia, Pneumocystis _xprevention & control
650	0	4	_aRifabutin _xtherapeutic use
650	0	4	_aToxoplasmosis _xprevention & control
650	0	4	_aTrimethoprim, Sulfamethoxazole Drug Combination _xtherapeutic use
650	0	4	_aTuberculosis, Pulmonary _xprevention & control
700	1		_aWilkinson, David
773	0		_tClinical evidence _gno. 13 _gp. 834-53
999			_c15771223 _d15771223